IL287693A - A new crispr nuclease called omni-50 - Google Patents
A new crispr nuclease called omni-50Info
- Publication number
- IL287693A IL287693A IL287693A IL28769321A IL287693A IL 287693 A IL287693 A IL 287693A IL 287693 A IL287693 A IL 287693A IL 28769321 A IL28769321 A IL 28769321A IL 287693 A IL287693 A IL 287693A
- Authority
- IL
- Israel
- Prior art keywords
- crispr nuclease
- novel omni
- omni
- novel
- crispr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841046P | 2019-04-30 | 2019-04-30 | |
| US201962897806P | 2019-09-09 | 2019-09-09 | |
| US201962931630P | 2019-11-06 | 2019-11-06 | |
| US202062959672P | 2020-01-10 | 2020-01-10 | |
| US202062991285P | 2020-03-18 | 2020-03-18 | |
| PCT/US2020/030782 WO2020223514A2 (en) | 2019-04-30 | 2020-04-30 | Novel omni-50 crispr nuclease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL287693A true IL287693A (en) | 2021-12-01 |
Family
ID=73029467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287693A IL287693A (en) | 2019-04-30 | 2021-10-28 | A new crispr nuclease called omni-50 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11666641B2 (https=) |
| EP (1) | EP3963061A4 (https=) |
| JP (2) | JP2022531347A (https=) |
| KR (2) | KR20250060327A (https=) |
| CN (1) | CN114127274A (https=) |
| AU (2) | AU2020266587B2 (https=) |
| BR (1) | BR112021021912A2 (https=) |
| CA (1) | CA3135759A1 (https=) |
| IL (1) | IL287693A (https=) |
| WO (1) | WO2020223514A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| US11946077B2 (en) | 2020-06-04 | 2024-04-02 | Emendobio Inc. | OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR nucleases |
| WO2022098693A1 (en) * | 2020-11-04 | 2022-05-12 | Emendobio Inc. | Novel omni-50 crispr nuclease-rna complexes |
| US20240175013A1 (en) * | 2020-12-14 | 2024-05-30 | Emendobio Inc. | Biallelic knockout of trac |
| WO2022132765A1 (en) * | 2020-12-14 | 2022-06-23 | Emendobio Inc. | Biallelic knockout of b2m |
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| KR20230142740A (ko) | 2021-02-08 | 2023-10-11 | 에멘도바이오 인코포레이티드 | Omni-103 crispr 뉴클레아제 |
| IL307855A (en) * | 2021-04-22 | 2023-12-01 | Emendobio Inc | OMNI CRISPR Nucleases 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226 , 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 news |
| IL310730A (en) * | 2021-08-12 | 2024-04-01 | Emendobio Inc | Engineered high fidelity omni-50 nuclease variants |
| JP2024540558A (ja) * | 2021-11-19 | 2024-10-31 | エメンドバイオ・インコーポレイテッド | 新規なｏｍｎｉ ｃｒｉｓｐｒヌクレアーゼ |
| US20250043260A1 (en) * | 2021-12-01 | 2025-02-06 | Emendobio Inc. | Engineered High Activity Omni-79 Nuclease Variants |
| US20260021141A1 (en) * | 2022-07-15 | 2026-01-22 | Emendobio Inc. | Strategies For Knock-Ins At APLP2 Safe Harbor Sites |
| WO2024042165A2 (en) * | 2022-08-26 | 2024-02-29 | UCB Biopharma SRL | Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases |
| WO2025043140A1 (en) * | 2023-08-23 | 2025-02-27 | Emendobio Inc. | Methods and compositions for modifying expression of a mutant transforming growth factor beta induced (tgfbi) allele |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2334794B8 (en) | 2008-09-15 | 2017-04-19 | The Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2015134812A1 (en) * | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
| WO2017024047A1 (en) | 2015-08-03 | 2017-02-09 | Emendobio Inc. | Compositions and methods for increasing nuclease induced recombination rate in cells |
| ES2942309T3 (es) | 2015-11-04 | 2023-05-31 | Vertex Pharma | Materiales y métodos para el tratamiento de hemoglobinopatías |
| CN105567735A (zh) * | 2016-01-05 | 2016-05-11 | 华东师范大学 | 一种凝血因子基因突变的定点修复载体系统及方法 |
-
2020
- 2020-04-30 WO PCT/US2020/030782 patent/WO2020223514A2/en not_active Ceased
- 2020-04-30 EP EP20799462.5A patent/EP3963061A4/en active Pending
- 2020-04-30 KR KR1020257013727A patent/KR20250060327A/ko active Pending
- 2020-04-30 BR BR112021021912A patent/BR112021021912A2/pt unknown
- 2020-04-30 JP JP2021564834A patent/JP2022531347A/ja active Pending
- 2020-04-30 KR KR1020217037743A patent/KR102802134B1/ko active Active
- 2020-04-30 US US17/594,761 patent/US11666641B2/en active Active
- 2020-04-30 AU AU2020266587A patent/AU2020266587B2/en active Active
- 2020-04-30 CN CN202080032631.5A patent/CN114127274A/zh active Pending
- 2020-04-30 CA CA3135759A patent/CA3135759A1/en active Pending
-
2021
- 2021-10-28 IL IL287693A patent/IL287693A/en unknown
-
2023
- 2023-04-06 US US18/296,798 patent/US20240226246A9/en active Pending
-
2024
- 2024-01-05 JP JP2024000768A patent/JP2024050582A/ja active Pending
- 2024-04-04 AU AU2024202171A patent/AU2024202171A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250060327A (ko) | 2025-05-07 |
| BR112021021912A2 (pt) | 2022-01-18 |
| AU2020266587A1 (en) | 2021-12-16 |
| EP3963061A2 (en) | 2022-03-09 |
| KR20220012245A (ko) | 2022-02-03 |
| US20240131121A1 (en) | 2024-04-25 |
| KR102802134B1 (ko) | 2025-05-07 |
| JP2022531347A (ja) | 2022-07-06 |
| EP3963061A4 (en) | 2023-02-08 |
| US11666641B2 (en) | 2023-06-06 |
| AU2020266587B2 (en) | 2024-01-04 |
| US20220202913A1 (en) | 2022-06-30 |
| JP2024050582A (ja) | 2024-04-10 |
| AU2024202171A1 (en) | 2024-06-27 |
| WO2020223514A2 (en) | 2020-11-05 |
| WO2020223514A3 (en) | 2020-12-24 |
| US20240226246A9 (en) | 2024-07-11 |
| CN114127274A (zh) | 2022-03-01 |
| CA3135759A1 (en) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287693A (en) | A new crispr nuclease called omni-50 | |
| GB201903079D0 (en) | Process | |
| GB201903080D0 (en) | Process | |
| IL289589A (en) | New methods | |
| GB201900665D0 (en) | 06557607002 | |
| GB201901061D0 (en) | Process | |
| GB2586327B (en) | Process | |
| GB201916427D0 (en) | Process | |
| GB201901069D0 (en) | Process | |
| GB201918699D0 (en) | Process | |
| GB201905107D0 (en) | Process | |
| GB201902646D0 (en) | Process | |
| GB201916601D0 (en) | 81989-gb-reg-org-nat-1 | |
| GB201913817D0 (en) | Process | |
| ZA202101681B (en) | Pacas9 nuclease | |
| GB202010889D0 (en) | Process | |
| GB2591987B (en) | Process | |
| GB201914325D0 (en) | Novel meethod | |
| GB202404562D0 (en) | Process | |
| GB201904741D0 (en) | Novel process | |
| GB202013791D0 (en) | Tidysqueeze 9 | |
| GB201911762D0 (en) | Novel methods | |
| GB201911764D0 (en) | Novel Methods | |
| GB201918773D0 (en) | TidySqueeze 8 | |
| CA187366S (en) | Hoodie |